Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Hematology"
DOI: 10.1007/s12185-021-03276-7
Abstract: Emicizumab reduces bleeding events in patients with severe hemophilia A (HA). The coagulation potential of emicizumab at a clinical dose appears to correspond to about 15 IU/dL of factor VIII activity (FVIII:C), the equivalent of… read more here.
Keywords: coagulation potential; hemophilia patients; emi pwha; bleeding ... See more keywords
Factor VIII mutated with Lys1813Ala within the factor IXa-binding region enhances intrinsic coagulation potential
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2022008187
Abstract: Key Points • K1813 in the FVIII A3 domain, considered to be an FXa-binding site, is responsible for the A2 subunit dissociation of FVIIIa.• The FVIII-K1813A mutant showed higher global coagulation potential vs WT because… read more here.
Keywords: mutated lys1813ala; viii mutated; factor; factor viii ... See more keywords